Skip to content

ABBREVIATE: Continuation vs. Discontinuation of Beta-Blockers in patients with coronary heart disease

Patients with heart disease are often prescribed many medications and these patients may experience drug interactions or negative drug related side effects. With newer medications and treatments available, it is not well known whether older drugs, such as beta-blockers, are still an effective and safe option for treating heart disease. Some evidence suggests beta-blockers should be continued, whereas other evidence suggests beta-blockers might cause unnecessary harm. The study hopes to determine whether continuation or discontinuation of beta-blockers will affect long term cardiovascular outcomes. The study investigators will also examine how beta-blockers continuation or discontinuation affects several quality of life measures.

null

Conditions de participation

  • Sexe:

    Female, Intersex, Male

  • Âges admissibles:

    21 and up

Critères de participation

Inclusion Criteria:
-age 21 or older (no maximum age)
-stable ischemic heart disease (aka coronary artery disease)
-currently prescribed beta-blocker medication(s) by your doctor
Exclusion Criteria:
-heart failure (left ventricular ejection fraction less than 40%)
-recent heart attack (less than 6 months ago)
-you are not eligible to stop beta-blocker therapy according to your doctor
-uncontrolled high blood pressure or angina (i.e., chest pain) symptoms
-unable to follow study instructions or complete study requirements
-life expectancy less than 1 year
-participation in another study involving beta-blockers or other medications for angina

Lieu de l'étude

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

ABBREVIATE Study Coordinator

[email protected]
780-407-3572
Étude parrainée par
University of Alberta
Participants recherchés
Plus d'informations
ID de l'étude: Pro00113192